Cart
sales@molnova.com
GPRP
CAS No. 67869-62-9
GPRP( —— )
Catalog No. M34267 CAS No. 67869-62-9
GPRP (Gly-Pro-Arg-Pro) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein IIb/IIIa complex (glycoprotein IIb/IIIa receptor).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGPRP
-
NoteResearch use only, not for human use.
-
Brief DescriptionGPRP (Gly-Pro-Arg-Pro) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein IIb/IIIa complex (glycoprotein IIb/IIIa receptor).
-
DescriptionGPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number67869-62-9
-
Formula Weight425.48
-
Molecular FormulaC18H31N7O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : ≥ 50 mg/mL (117.51 mM)DMSO : 20.83 mg/mL (48.96 mM; Ultrasonic )
-
SMILESC([C@@H](NC(=O)[C@H]1N(C(CN)=O)CCC1)CCCNC(=N)N)(=O)N2[C@H](C(O)=O)CCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
ALG1001
ALG1001 (Risuteganib, ALG-1001) is a first-in-class, RGD class oligopeptide that inhibits integrin receptors (αvβ3, αvβ5, and α5β1) associated with angiogenesis.
-
Fibronectin CS1 Pept...
he connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. CS1 peptide of fibronectin, which lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models. The use of Fibronectin CS1 Peptide might offer a promising therapeutic approach for combating and preventing cancer metastasis.
-
Firategrast
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist that reduces the transport of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.
